Past, present and (foreseeable) future of biological anti-TNF alpha therapy
GM Leone, K Mangano, MC Petralia, F Nicoletti… - Journal of Clinical …, 2023 - mdpi.com
Due to the key role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of
immunoinflammatory diseases, TNF-α inhibitors have been successfully developed and …
immunoinflammatory diseases, TNF-α inhibitors have been successfully developed and …
Effect of DMARDs on the immunogenicity of vaccines
Y van Sleen, KSM van der Geest… - Nature Reviews …, 2023 - nature.com
Vaccines are important for protecting individuals at increased risk of severe infections,
including patients undergoing DMARD therapy. However, DMARD therapy can also …
including patients undergoing DMARD therapy. However, DMARD therapy can also …
COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation
R Lev-Tzion, G Focht, R Lujan, A Mendelovici… - Clinical …, 2022 - Elsevier
Background & Aims Studies have shown decreased response to coronavirus disease 2019
(COVID-19) vaccinations in some populations. In addition, it is possible that vaccine …
(COVID-19) vaccinations in some populations. In addition, it is possible that vaccine …
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a …
JL Alexander, Z Liu, DM Sandoval… - The Lancet …, 2022 - thelancet.com
Background COVID-19 vaccine-induced antibody responses are reduced in patients with
inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We …
inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We …
[HTML][HTML] Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
RM Dayam, JC Law, RL Goetgebuer, GYC Chao… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Limited information is available on the impact of immunosuppressants on
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID) …
SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients–a phase four study comparing …
A Wagner, E Garner-Spitzer, AM Schötta… - Frontiers in …, 2022 - frontiersin.org
Background Individuals with secondary immunodeficiencies belong to the most vulnerable
groups to succumb to COVID-19 and thus are prioritized for SARS-CoV-2 vaccination …
groups to succumb to COVID-19 and thus are prioritized for SARS-CoV-2 vaccination …
Favorable vaccine-induced SARS-CoV-2–specific T cell response profile in patients undergoing immune-modifying therapies
BACKGROUND Patients undergoing immune-modifying therapies demonstrate a reduced
humoral response after COVID-19 vaccination, but we lack a proper evaluation of the effect …
humoral response after COVID-19 vaccination, but we lack a proper evaluation of the effect …
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Objective Antitumour necrosis factor (TNF) drugs impair serological responses following
SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA) …
SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA) …
The T-cell response to SARS-CoV-2 vaccination in inflammatory bowel disease is augmented with anti-TNF therapy
Lay Summary T-cell and antibody responses to severe acute respiratory syndrome
coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T …
coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T …
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …